Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713876 | 0.89 | POLB (0.43) | POLBHTTLMNATDP1ALDH1A1 | |
| SCHEMBL6860836 | 0.82 | FFAR4 (0.42) | POLBHTTLMNATDP1ALDH1A1 | |
| SCHEMBL6859136 | 0.82 | POLB (0.50) | POLBLMNAALDH1A1P2RX4MAPT | |
| SCHEMBL6853881 | 0.80 | SIRT1 (0.53) | HTTLMNATDP1ALDH1A1MAPT | |
| SCHEMBL7708641 | 0.72 | ALDH1A1 (0.43) | POLBHTTLMNAALDH1A1MAPT | |
| SCHEMBL7708663 | 0.71 | POLB (0.46) | POLBLMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6492849 | 0.71 | ITGB3 (0.50) | ALDH1A1MAPTAKR1B1FFAR4 | |
| SCHEMBL6493305 | 0.71 | ITGB3 (0.50) | ALDH1A1MAPTAKR1B1FFAR4 | |
| SCHEMBL18143314 | 0.70 | SIRT1 (0.52) | HTTLMNATDP1ALDH1A1MAPT | |
| SCHEMBL16851476 | 0.70 | SIRT1 (0.52) | HTTLMNATDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | ITGB1, ITGA1, ITGB3 | POLB 4738/4885HTT 4868/4885LMNA 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.